bluebird bio, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$6.7M
Doctors Paid
236
Transactions
635
2024 Total
$1.9M
Payment Breakdown by Category
Research$6.2M (92.9%)
Consulting$273,233 (4.1%)
Royalty/License$38,481 (0.6%)
Food & Beverage$18,360 (0.3%)
Travel$13.88 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.2M | 220 | 92.9% |
| Consulting Fee | $273,233 | 79 | 4.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $80,500 | 5 | 1.2% |
| Grant | $61,000 | 5 | 0.9% |
| Royalty or License | $38,481 | 5 | 0.6% |
| Food and Beverage | $18,360 | 319 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $1,000 | 1 | 0.0% |
| Travel and Lodging | $13.88 | 1 | 0.0% |
Payments by Type
Research
$6.2M
220 transactions
General
$472,588
415 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects < 17 Years of Age With Cerebral Adrenoleukodystrophy (CALD) | $2.1M | 0 | 17 |
| A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease | $862,973 | 0 | 44 |
| Longterm Follow-Up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product | $795,572 | 0 | 27 |
| Longterm Follow up of Subjects with Hemoglobinopathies Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector | $780,148 | 0 | 30 |
| A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent Thalassemia by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral A T87Q Globin Vector in Subjects <50 Years of Age | $680,312 | 0 | 39 |
| Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector | $465,139 | 0 | 38 |
| SRA for HGB 206, LTF 307 | $249,455 | 0 | 5 |
| PROJECT_SICKLE_CURE | $151,012 | 0 | 1 |
| A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the BB305 Lentiviral Vector in Subjects With Sickle Cell Disease | $78,103 | 0 | 12 |
| A Safety and Effectiveness Registry Study of Patients with β‑Thalassemia Treated with Betibeglogene Autotemcel (Glostar) | $37,420 | 0 | 3 |
| Evidera SOW TDT QOL in US Data Collection & Report (USMA22045) | $23,500 | 0 | 2 |
| A Postmarketing, Prospective, Multicenter, Observational, Long-Term Safety and Effectiveness Registry Study of Patients with Cerebral Adrenoleukodystrophy (CALD) Treated with Elivaldogene Autotemcel (Stargazer) | $3,190 | 0 | 1 |
| A Phase 3 Singe Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent b-Thalassemia, who do not have b 0 /b0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral b A-T87Q-Globin Vector in Subjects >12 and <50 Years of Age | $1,325 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Richard Champlin, M.d, M.D | Hematology & Oncology | Houston, TX | $1,238 | $0 |
| Dr. Allison Remiker, M.d, M.D | Pediatric Hematology-Oncology | Milwaukee, WI | $1,220 | $0 |
| Dr. Jennifer Yu, M.d, M.D | Pediatric Hematology-Oncology | San Diego, CA | $1,205 | $0 |
| Jonathan Fish, M.d, M.D | Pediatric Hematology-Oncology | New Hyde Park, NY | $980.00 | $0 |
| Shunyou Gong, M.d, M.D | Anatomic Pathology & Clinical Pathology | Chicago, IL | $900.00 | $0 |
| Ivan Borrello, M.d, M.D | Medical Oncology | Tampa, FL | $895.73 | $0 |
| Jennifer Tran, D.o, D.O | Student in an Organized Health Care Education/Training Program | Houston, TX | $740.00 | $0 |
| Eduardo Sotomayor, Md, MD | Hematology & Oncology | Tampa, FL | $623.20 | $0 |
| Rachel Phelan, Md, Mph, MD, MPH | Pediatric Emergency Medicine | Milwaukee, WI | $610.00 | $0 |
| Dana Leblanc, Md, MD | Pediatric Hematology-Oncology | New Orleans, LA | $518.19 | $0 |
| Zachary Leblanc, M.d, M.D | Pediatric Hematology-Oncology | New Orleans, LA | $518.19 | $0 |
| Dr. Bradley Fletcher, Md, MD | Hematology & Oncology | Tampa, FL | $499.68 | $0 |
| David Jacobsohn, Md, MD | Pediatric Hematology-Oncology | Chicago, IL | $483.31 | $0 |
| Sara Graciaa, Cpnp, CPNP | Pediatrics | Atlanta, GA | $440.00 | $0 |
| Jennifer Hanle, Agpcnp, AGPCNP | Nurse Practitioner | Tampa, FL | $432.24 | $0 |
| Dr. Lazaros Lekakis, Md, MD | Hematology & Oncology | Miami, FL | $335.95 | $0 |
| Maria Velez-Yanguas, Md, MD | Pediatrics | New Orleans, LA | $320.36 | $0 |
| Dr. Corey Falcon, M.d, M.D | Pediatric Hematology-Oncology | Metairie, LA | $313.60 | $0 |
| Jennifer Jaroscak, Md, MD | Pediatric Hematology-Oncology | Durham, NC | $293.98 | $0 |
| Neena Kapoor, Md, MD | Pediatric Hematology-Oncology | Los Angeles, CA | $249.32 | $0 |
| Jeanne Boudreaux, Md, MD | Hematology & Oncology | Atlanta, GA | $241.06 | $0 |
| Courtney Thornburg, M.d, M.D | Pediatrics | San Diego, CA | $225.00 | $0 |
| Ami Shah, Md, MD | Pediatrics | Palo Alto, CA | $222.15 | $0 |
| Dr. Elizabeth Krieger, M.d, M.D | Student in an Organized Health Care Education/Training Program | Richmond, VA | $214.88 | $0 |
| Laura Finn, M.d, M.D | Internal Medicine | New Orleans, LA | $214.45 | $0 |
About bluebird bio, Inc.
bluebird bio, Inc. has made $6.7M in payments to 236 healthcare providers, recorded across 635 transactions in the CMS Open Payments database. In 2024, the company paid $1.9M. The top product by payment volume is SKYSONA ($3.1M).
Payments were distributed across 32 medical specialties. The top specialty by payment amount is Pediatric Hematology-Oncology ($154,702 to 72 doctors).
Payment categories include: Food & Beverage ($18,360), Consulting ($273,233), Research ($6.2M), Travel & Lodging ($13.88), Royalties ($38,481).
bluebird bio, Inc. is associated with 3 products in the CMS Open Payments database.